During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by ...

Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option. First ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin.

The randomized study compared combination immunotherapy with nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) vs. nivolumab alone in patients with ...

a type of skin cancer. It has since been authorized to treat kidney cancer, colorectal cancer, and non-small cell lung cancer (NSCLC). Often, Yervoy is paired with fellow checkpoint inhibitor Opdivo ...

The melanoma pathologist had surgery early last week which confirmed the recurrence of a brain tumour. He was advised by his medical team that he only had months to live. "I am positive about it ...

In October 2015, the company’s Opdivo and Yervoy combination regimen was the first immuno-oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently ...

The combination of Opdivo and Yervoy is also approved for metastatic melanoma, first-line treatment of adult patients with metastatic non-small cell lung cancer, first-line treatment of adult ...